OBT is focused on the development of targeted antibody-based medicines for oncology. OBT’s strategy is to develop innovative antibody-based cancer drugs, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP® proteomic database.
Through its alliances with world leaders in antibody development, OBT is in an unrivalled position to convert its novel targets into an exciting pipeline of first-in-class therapeutics for the treatment of cancer. OBT’s pipeline will deliver cost-effective medicines to fulfill the major unmet medical need of cancer patients.
Beyond PDL1: OBT has recently discovered a novel T cell modulatory axis, OX001R/L, which is involved in cancer immune escape independent of the PD1/PDL1 axis.